» Articles » PMID: 39802901

Fatty Acid Metabolism: A New Target for Nasopharyngeal Carcinoma Therapy

Overview
Date 2025 Jan 13
PMID 39802901
Authors
Affiliations
Soon will be listed here.
Abstract

Lipid metabolic reprogramming is considered one of the most prominent metabolic abnormalities in cancer, and fatty acid metabolism is a key aspect of lipid metabolism. Recent studies have shown that fatty acid metabolism and its related lipid metabolic pathways play important roles in the malignant progression of nasopharyngeal carcinoma (NPC). NPC cells adapt to harsh environments by enhancing biological processes such as fatty acid metabolism, uptake, production, and oxidation, thereby accelerating their growth. In addition, the reprogramming of fatty acid metabolism plays a central role in the tumor microenvironment (TME) of NPC, and the phenotypic transformation of immune cells is closely related to fatty acid metabolism. Moreover, the reprogramming of fatty acid metabolism in NPC contributes to immune escape, which significantly affects disease treatment, progression, recurrence, and metastasis. This review explores recent advances in fatty acid metabolism in NPC and focuses on the interconnections among metabolic reprogramming, tumor immunity, and corresponding therapies. In conclusion, fatty acid metabolism represents a potential target for NPC treatment, and further exploration is needed to develop strategies that target the interaction between fatty acid metabolic reprogramming and immunotherapy.

References
1.
Tracz-Gaszewska Z, Dobrzyn P . Stearoyl-CoA Desaturase 1 as a Therapeutic Target for the Treatment of Cancer. Cancers (Basel). 2019; 11(7). PMC: 6678606. DOI: 10.3390/cancers11070948. View

2.
Su Z, Siak P, Lwin Y, Cheah S . Epidemiology of nasopharyngeal carcinoma: current insights and future outlook. Cancer Metastasis Rev. 2024; 43(3):919-939. DOI: 10.1007/s10555-024-10176-9. View

3.
Liu X, Hu Z, Qu J, Li J, Gong K, Wang L . AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-κB axis in nasopharyngeal carcinoma. Int J Biol Sci. 2021; 17(3):756-767. PMC: 7975703. DOI: 10.7150/ijbs.52927. View

4.
Liang J, Zhou X, Long H, Li C, Wei J, Yu X . Recent advance of ATP citrate lyase inhibitors for the treatment of cancer and related diseases. Bioorg Chem. 2023; 142:106933. DOI: 10.1016/j.bioorg.2023.106933. View

5.
Wang Y, Guo Z, Isah A, Chen S, Ren Y, Cai H . Lipid metabolism and tumor immunotherapy. Front Cell Dev Biol. 2023; 11:1187989. PMC: 10228657. DOI: 10.3389/fcell.2023.1187989. View